BPTS Stock - Biophytis S.A.
Unlock GoAI Insights for BPTS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-803,000 | $-484,000 | $-311,000 | $-280,000 | $-262,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,333,000 | $-23,272,000 | $-26,815,000 | $-13,942,000 | $-15,682,000 |
| Net Income | $-17,026,000 | $-24,216,000 | $-31,163,000 | $-25,517,000 | $-18,946,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-12.55 | $-56.06 | $-105.64 | $-172.41 | $-451.10 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
BPTSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 7, 2025 | — | — | — | — |
Q3 2024 | Sep 25, 2024 | — | $-1.79 | — | — |
Q2 2024 | Apr 8, 2024 | $-0.30 | $-5.37 | -1690.3% | ✗ MISS |
Q3 2023 | Jul 21, 2023 | $-0.47 | $-10.34 | -2124.4% | ✗ MISS |
Q2 2023 | Apr 18, 2023 | $-1.12 | $-25.22 | -2160.2% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | — | $-17.55 | — | — |
Q2 2022 | May 26, 2022 | — | $-32.27 | — | — |
Q3 2021 | Sep 17, 2021 | — | $-28.40 | — | — |
Q1 2021 | Feb 26, 2021 | — | $-35.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-82.85 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-97.31 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-174.05 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-297.32 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-193.69 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-265.67 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-322.80 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-286.07 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-266.94 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-256.29 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-128.76 | — | — |
Latest News
Frequently Asked Questions about BPTS
What is BPTS's current stock price?
What is the analyst price target for BPTS?
What sector is Biophytis S.A. in?
What is BPTS's market cap?
Does BPTS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BPTS for comparison